Tango Therapeutics Inc

TNGX

Add to Watchlist

20.450USD

-4.420-17.77%

Market hours （ET）Quotes delayed by 15 min

Tango Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

24 / 382

Overall Ranking

113 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Tango Therapeutics Inc Highlights

StrengthsRisks

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 70.79% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 62.38M.

Undervalued

The company’s latest PE is -29.96, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 177.88M shares, increasing 16.78% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 102.00 shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

27.400

Target Price

+7.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Tango Therapeutics Inc is 8.23, ranking 42 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 14.14%.

Score

Industry at a Glance

Previous score

8.23

Change

0



Financials

8.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Tango Therapeutics Inc is 6.19, ranking 305 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -29.96, which is -96.95% below the recent high of -0.91 and -5.98% above the recent low of -31.75.

Score

Industry at a Glance

Previous score

6.19

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Tango Therapeutics Inc is 8.67, ranking 72 out of 382 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 15.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Tango Therapeutics Inc is 7.54, ranking 87 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 28.60 and the support level at 20.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.02

Change

-1.48

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Tango Therapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.32%, representing a quarter-over-quarter increase of 24.30%. The largest institutional shareholder is Steven Cohen, holding a total of 1.97M shares, representing 1.37% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Farallon Capital Management, L.L.C.

13.06M

+21.42%

TCG Crossover Management, LLC

12.76M

+49.51%

Boxer Capital Management, LLC

10.88M

+11.31%

Adage Capital Management, L.P.

10.61M

+322.46%

Woodline Partners LP

10.07M

+67.04%

BlackRock Institutional Trust Company, N.A.

7.76M

+52.02%

Nextech Invest, Ltd.

7.27M

+31.30%

Third Rock Ventures, LLC

6.37M

-21.00%

State Street Investment Management (US)

6.22M

+84.79%

Invus Public Equities Advisors, LLC

8.17M

+38.79%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tango Therapeutics Inc is 4.22, ranking 94 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Tango Therapeutics Inc

TNGX

7.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.66 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment